Loading stock data…
$3.46-0.11 (-2.95%)
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States.
Immuneering Corporation in the Healthcare sector is trading at $3.46 with a market capitalization of $309M. Wall Street consensus targets $17.17 (6 analysts), implying a +396.9% move over the next 12 months. The stock is currently near its 52-week low of $3.43, remaining 30.1% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 19 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$19.00M↓ | -$15.33M↓ | -$13.75M↑ | -$15.38M↓ | -$14.76M |
| Net Income | -$17.27M↓ | -$13.46M↓ | -$11.58M↑ | -$14.96M↓ | -$14.43M |
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat...